Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction
Adeno-associated virus (AAV) gene therapy has been successfully applied in hemophilia patients excluding patients with inhibitors. During the coagulation pathway, activated factor V (FVa) functions downstream as a cofactor of activated factor X (FXa) to amplify thrombin generation. We hypothesize th...
Main Authors: | Junjiang Sun, Xiaojing Chen, Zheng Chai, Hongqian Niu, Amanda L. Dobbins, Timothy C. Nichols, Chengwen Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.880763/full |
Similar Items
-
Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog
by: Wenwei Shao, et al.
Published: (2022-01-01) -
Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort
by: Sara Boyce, et al.
Published: (2022-05-01) -
The intersection of vector biology, gene therapy, and hemophilia
by: Leszek Lisowski, et al.
Published: (2021-08-01) -
Status and Prospect of Gene Therapy for Hemophilia
by: DAI Xinyue, et al.
Published: (2022-10-01) -
Advanced biomanufacturing and evaluation of adeno-associated virus
by: Kai Chen, et al.
Published: (2024-02-01)